InsidersTradesSigma
Total declarations
Company
▲ Purchases (3 ops.)
▼ Sales (3 ops.)
Browse the full record of transactions filed by YASHA MITROTTI VENTURA, Directeur Exécutif, Applications Industrielles chez bioMérieux. Officer active across 1 companies, notably BIOMERIEUX. In total, 8 filings have been recorded. Total volume traded: €615k. The latest transaction was disclosed on 9 September 2025 — Cession. Regulator: AMF. All data is openly available.
Declarations8 total
€263,3172,299 shares@ €114.53560.0020% mcap42.8% of flow
Actions gratuitesEuronext Paris
2025DD1057334·
04,625 shares0
Actions gratuitesHors plateforme de négociation
2025DD1057274·
Ideal exit: 6 Jun 2026 (T+270)
04,375 shares0
ActionHors plateforme de négociation
2024DD994712·
€179,9511,637 shares@ €109.92750.0014% mcap29.3% of flow
ActionEuronext Paris
2024DD994714·
03,625 shares0
ActionHors plateforme de négociation
2023DD926414·
€171,8971,790 shares@ €96.0320.0013% mcap27.9% of flow
ActionEuronext Paris
2023DD926418·
05,444 shares0
ActionAcquisition d'actions gratuites
2022DD824951·
Ideal exit: 23 Nov 2022 (T+270)
05,444 shares0
ActionHors plateforme de négociation
2022DD825459·
Ideal exit: 23 Nov 2022 (T+270)
8 of 8 declarations
About YASHA MITROTTI VENTURA
Yasha Mitrotti Ventura holds a senior leadership position at bioMérieux as Executive Vice President, Industrial Applications. In this role, he oversees one of the group’s most strategically important businesses, focused on industrial microbiology and on solutions for food, pharmaceutical, biotechnology, and other production environments where quality, traceability, and contamination control are critical. bioMérieux identifies him as a member of its executive leadership team and the executive responsible for Industrial Applications, confirming his importance within the company’s governance structure. His mandate is closely linked to the company’s broader transition toward higher-value, innovation-driven industrial quality solutions. In recent corporate communications, Yasha Mitrotti has been the spokesperson for several initiatives tied to product innovation and market expansion, including bioMérieux’s advanced diagnostics for the pharmaceutical industry and advanced therapies. He also featured in the 2024 announcement of a partnership between bioMérieux and Mérieux NutriSciences with major global food industry players, designed to build a collaborative, data-driven model that improves food safety and helps anticipate risk. One of the most notable developments associated with his scope is the 2025 acquisition of Accellix, which strengthened bioMérieux’s offering in advanced therapy quality control by adding capabilities related to cell purity and viability. That transaction reflects a growth strategy based on innovation and on broadening the company’s addressable market in high-growth, regulated segments. More broadly, his professional profile appears to combine industrial microbiology expertise, quality and regulatory awareness, product innovation, and international business leadership. In an environment where industrial customers demand speed, reliability, and scientific robustness, Yasha Mitrotti Ventura stands out as an executive focused on operational execution, value creation, and supporting the healthcare and agri-food industries in their safety and performance challenges.
